Tags : nCounter FLEX System

Veracyte Signs an Exclusive License Agreement with NanoString for its

Shots: NanoString to receive $40M in cash & $10M in Veracyte’s stock along with $10M as milestones.  Veracyte to get an exclusive global right to develop and commercialize diagnostic tests on NanoString’s nCounter FLEX system Veracyte will expand nCounter-based diagnostic portfolio utilizing its own test and has obtained rights to NanoString’s 510(k)-cleared Prosigna breast cancer […]Read More